Would you like to know more about the OASIS-HAE study?
UPDATE: Enrollment for our Phase-III, placebo-controlled trial, Oasis-HAE, is now closed. Our open-label extension study, Oasis Plus, remains open to enrollment for individuals with Hereditary Angioedema currently on prophylactic therapy.
The Oasis Plus study is a clinical research study sponsored by Ionis Pharmaceuticals, a company developing a potential new therapy for HAE. This study will help researchers learn whether an investigational study drug is safe and effective for people with HAE when given over a long-term period.
HAE is a rare and potentially life-threatening genetic disease that causes painful swelling attacks in various parts of the body, mainly in the hands, feet, face, throat, and stomach area. Swelling in the airway can restrict breathing and be fatal. A HAE attack may be triggered by emotional trauma or stress; however, an attack often occurs without a known trigger. Attacks can occur without warning and last up to several days if untreated.
HAE is a rare, potentially life-threatening disease that causes painful swelling attacks, mainly in the hands, feet, face, throat, and stomach area. Swelling in the airway can restrict breathing and be fatal. Attacks can occur without warning and last up to several days. Most cases of HAE are caused by a genetic mutation that affects production of a protein called C1-inhibitor. HAE affects approximately 20,000 people in the U.S. and Europe. There are medicines available to treat and prevent HAE attacks. Researchers are currently looking for new treatment options that might work better or help improve people’s quality of life.
This study will help researchers learn if the study drug is safe and effective for people with HAE when given over a long-term period. Participants in Oasis Plus are either:
You may qualify for the study if you meet the following requirements:
The study drug is called donidalorsen (don-id-a-lor-sen). Donidalorsen is designed to lower the amount of a protein called prekallikrein (PKK) in the body. By lowering PKK, donidalorsen may help reduce or prevent HAE attacks.
Donidalorsen is an injection that is administered under the skin of the upper arm, abdomen, or thigh.
For location information or questions, please contact us at [email protected] or 844-501-0233.